Solganick & Co.

SEPTEMBER 2, 2024

September 2, 2024 – The software mergers and acquisitions (M&A) marketplace has been bustling with activity in the first half of 2024, reflecting the sector’s robust growth and strategic consolidations. billion acquisition of Ansys, a move aimed at bolstering its software capabilities and expanding its market footprint.

Mergers and Acquisitions 52

Mergers and Acquisitions Acquisitions Mergers M&A 52

Global Newswire by Notified: M&A

APRIL 29, 2024

The acquisition of Camlab bolsters Calibre Scientific’s growing product and service portfolio across the United Kingdom. The acquisition of Camlab bolsters Calibre Scientific’s growing product and service portfolio across the United Kingdom.

Pharmaceutical 45

Pharmaceutical Food Portfolio Acquisitions 45

Global Newswire by Notified: M&A

JULY 8, 2025

Accessibility: Skip TopNav Medvantx Acquires RxS to Broaden Integrated Access & Engagement Solutions for Life Science Combined company will leverage services and technology platforms to offer a broad portfolio of integrated solutions to pharmaceutical and device manufacturers July 08, 2025 08:00 ET | Source: Medvantx, Inc.

Medical 40

Medical Pharmaceutical Accountant Manufacturing 40

OfficeHours

JANUARY 26, 2024

Buyout houses from Thoma Bravo to Permira are putting portfolio company sales high on the agenda for early 2024, as the industry seeks to return money to investors after a challenging period for exiting holdings. Some dealmakers claim the impact of elections on mergers and acquisitions is minimal. First, they want to earn.

Private Equity 130

Private Equity Equities Mergers and Acquisitions M&A 130

Private Equity Info

JUNE 9, 2025

Two sectors stand out for their role in advancing healthcare: Pharmaceutical and Medicine Manufacturing This sector has been a magnet for PE interest due to its resilience, regulatory clarity, and innovation pipeline. That’s more than six times the number of outbound U.S.

Private Equity 52

Private Equity Equities Manufacturing Medical 52

Cooley M&A

JANUARY 23, 2024

While the year saw an overall decline in M&A activity (down 17% from 2022) , total pharmaceuticals and life sciences deal value in 2023 increased by approximately 50% compared to 2022. billion; Bristol Myer Squibb’s acquisition of RayzeBio for $4.1 billion; and Roche’s acquisition of Carmot Therapeutics for up to $3.1

M&A 52

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 52

Software Equity Group

JUNE 6, 2023

 Ideagen is a leading provider of software solutions to regulated and high-compliance industries, including pharmaceutical, aerospace and defense, and life sciences. The Tritan-Ideagen deal demonstrates the value of strategic acquisitions as a method for entering new markets and expanding globally.

M&A 52

M&A Mergers and Acquisitions Middle Market Acquisitions 52

Software Equity Group

AUGUST 20, 2024

One strategy gaining momentum is the acquisition of high-growth SaaS companies. This opens the door to significant investment and acquisition opportunities for SaaS companies from strategic buyers within and outside of the software industry. The company made 15 acquisitions in 2023. But value extends far beyond market access.

Investment 52

Investment Management Acquisitions Business 52

Cooley M&A

JANUARY 25, 2023

But it wasn’t all carve outs and concerned investors – even with the headwinds in the industry and beyond, there were still several traditional public M&A deals involving biotechnology or medical device companies, as large pharmaceutical companies continued to have cash to deploy for acquisitions.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Mergers and Inquisitions

NOVEMBER 1, 2023

They do not invest in risky biotech startups attempting to cure cancer (at least not within their traditional PE portfolios). PE firms view these companies as especially appealing since low multiples mean they can use higher debt percentages to fund the acquisitions. to consolidate their market power in specific regions. in biology.

Private Equity 59

Private Equity Healthcare Equities Middle Market 59

Devensoft

AUGUST 22, 2023

Understanding Freelance Modeling in M&A In the realm of mergers and acquisitions (M&A), freelance modeling emerges as a dynamic and adaptive methodology, offering a departure from traditional approaches. Consider a merger between a pharmaceutical company and a biotech startup.

M&A 52

M&A Business Mergers and Acquisitions Collaboration 52

Devensoft

AUGUST 24, 2023

By melding the proficiencies, assets, and potentials residing within distinct business sectors or entities under a single organizational umbrella, the practice of mergers and acquisitions unveils dormant possibilities, propels inventive evolution, and champions the delivery of unparalleled outcomes.

Business 52

Business Collaboration Mergers and Acquisitions Management 52

Cooley M&A

JANUARY 22, 2021

The second half of the year witnessed a rebound spurred by several multibillion-dollar deals, including Gilead’s acquisition of Immunomedics for nearly $21 billion and AstraZeneca’s proposed acquisition of Alexion Pharmaceuticals for $39 billion.

M&A 40

M&A Mergers and Acquisitions Collaboration Mergers 40

Cooley M&A

JANUARY 20, 2022

1] Major all-cash acquisitions have followed, such as Arena Pharmaceutical’s agreement to sell to Pfizer for $6.7 1] Major all-cash acquisitions have followed, such as Arena Pharmaceutical’s agreement to sell to Pfizer for $6.7 approved prescription cannabidiol medicine to its portfolio. With COVID?19

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Mergers 40

Global Newswire by Notified: M&A

MAY 21, 2025

BOSTON, May 21, 2025 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., This acquisition broadens Parateks commercial portfolio which now includes both its flagship antibiotic, NUZYRA (omadacycline), and Optinoses product XHANCE (fluticasone propionate). NASDAQ:OPTN). NASDAQ:OPTN).

Pharmaceutical 45

Pharmaceutical Portfolio Acquisitions Medical 45

Global Newswire by Notified: M&A

APRIL 7, 2025

April 07, 2025 (GLOBE NEWSWIRE) -- Surplus Solutions LLC (Surplus Solutions), a portfolio company of NMS Capital (NMS), announced today the acquisition of Certified Genetool (or the Company), a San Francisco-based provider of certified laboratory instruments and technical services. NEW YORK and WOONSOCKET, R.I.,

Portfolio 52

Portfolio Capital Pharmaceutical Acquisitions 52

CNBC: Investing

JUNE 12, 2025

To top that off, several of the names also pay dividends, which can help cushion investors' portfolios from market jolts. Last month, Goldman Sachs lifted its price target on the pharmaceutical giant to $176 from $172, placing Johnson & Johnson on its conviction list.

S&P 55

S&P Portfolio Stock Investment 55

Sun Acquisitions

FEBRUARY 11, 2025

As companies strive to balance profitability with environmental and social responsibility, mergers and acquisitions (M&A) are emerging as a strategic tool to accelerate sustainable growth. Through strategic acquisitions, businesses can access cutting-edge technologies, renewable energy sources, and expertise in sustainable operations.

M&A 66

M&A Mergers and Acquisitions Business Profitability 66

Focus Investment Banking

DECEMBER 20, 2024

Private equity-backed ophthalmology groups have seen significant growth over the last eight years, with more than 30 platforms establishing themselves in the market; most completing numerous add-on (individual practice) acquisitions. to a strategic buyer confirms the value retina practices hold for healthcare investors and operators.

Private Equity 52

Private Equity Healthcare Equities Sale 52

Focus Investment Banking

FEBRUARY 11, 2025

McKessons acquisition of PRISM Vision Group is an important milestone for private equitys investments in optometry practices. PRISM was founded in 2018 with Quad-C Managements acquisition of NJ Retina, a large Retina practice in New Jersey. Since then, PRISM has partnered with more than 20 ophthalmology groups throughout the Northeast.

Private Equity 52

Private Equity Healthcare Equities Medical 52

Cooley M&A

JANUARY 22, 2025

While global M&A deal value across sectors remained relatively flat overall , pharmaceuticals and life sciences M&A in 2024 dipped relative to the prior year. Indeed, the largest US biotech exit in 2024 was Vertex Pharmaceuticals $4.9 Total deal value is where the market really shed its weight down a remarkable 33.7%

M&A 64

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 64

Cooley M&A

FEBRUARY 15, 2017

We are seeing funds increasingly fundraising for tech plays and are acquiring the needed sector expertise to build their tech portfolios. The continued publicity and political focus on drug pricing has created uncertainty in valuing specialty pharmaceutical and biotech companies.

M&A 40

M&A IPO Pharmaceutical Valuation 40

InvestmentBank.com

MAY 18, 2021

The healthcare industry is formed of numerous subsectors including pharmaceutical services, diagnostics, medical technologies, and managed healthcare. Payor services and pharmaceutical services have generated the most return throughout 2016 and in 1Q 2017. The pharmaceutical industry is valued highly given the performance of buyouts.

Healthcare 40

Healthcare M&A Valuation Hospitality 40